Q-omics provides the consensus-scored FANCE profile across patient tissues and cancer cell-line models. FANCE expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FANCE is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FANCE RNA expression shows 21,981 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where FANCE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FANCE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FANCE survival associations across molecular data types. FANCE RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FANCE RNA expression–survival associations across cancer types. High FANCE expression shows unfavorable associations in ACC, LIHC and KIRP, but favorable associations in UCS, LUSC and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FANCE RNA expression.
This table summarizes FANCE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FANCE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FANCE shows higher tumor expression in HNSC, COAD, LIHC, BLCA, LUSC and CHOL. The HNSC box plot shows higher FANCE RNA expression in tumor versus normal tissue (log2 FC = +1.486, t-test p < 0.001).
This table shows molecular features associated with FANCE in patient tissues and cancer cell lines. In patient samples, FANCE shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FANCE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
